Cargando…

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with altered neural responses to emotional stimuli in the striatum and medial temporal lobe. Using a randomised, double-blind, parallel-group design, 33 CHR patients were randomised...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Cathy, Wilson, Robin, Appiah-Kusi, Elizabeth, Blest-Hopley, Grace, Brammer, Michael, Perez, Jesus, Murray, Robin M., Allen, Paul, Bossong, Matthijs G., McGuire, Philip, Bhattacharyya, Sagnik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487274/ https://www.ncbi.nlm.nih.gov/pubmed/32921794 http://dx.doi.org/10.1038/s41398-020-0862-2

Ejemplares similares

Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
por: Davies, Cathy, et al.
Publicado: (2021)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels
por: Bossong, Matthijs G, et al.
Publicado: (2018)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

Epigenetic Mediation of AKT1 rs1130233’s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing
por: Blest-Hopley, Grace, et al.
Publicado: (2021)

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2018)

O5.2. CBD MODULATION OF HIPPOCAMPAL GLUTAMATE IN PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2020)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
por: Appiah-Kusi, E., et al.
Publicado: (2020)

Regular cannabis use is associated with altered activation of central executive and default mode networks even after prolonged abstinence in adolescent users: Results from a complementary meta-analysis
por: Blest-Hopley, Grace, et al.
Publicado: (2019)

A Systematic Review of Human Neuroimaging Evidence of Memory-Related Functional Alterations Associated with Cannabis Use Complemented with Preclinical and Human Evidence of Memory Performance Alterations
por: Blest-Hopley, Grace, et al.
Publicado: (2020)

T99. LONG-TERM CANNABIS USE ASSOCIATED WITH ALTERED FUNCTIONING DURING VERBAL LEARNING
por: Blest-Hopley, Grace, et al.
Publicado: (2018)

Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use
por: Blest-Hopley, Grace, et al.
Publicado: (2019)

Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence
por: Blest-Hopley, Grace, et al.
Publicado: (2020)

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
por: Colizzi, Marco, et al.
Publicado: (2019)

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2019)

Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes
por: Modinos, Gemma, et al.
Publicado: (2021)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
por: Wilson, Robin Paul, et al.
Publicado: (2018)

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis
por: Sami, Musa, et al.
Publicado: (2020)

Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study
por: Patel, Rashmi, et al.
Publicado: (2016)

Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis
por: Egerton, Alice, et al.
Publicado: (2017)

The Impact of Cannabidiol on Human Brain Function: A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2021)

S224. DELTA-9-TETRAHYDROCANNABINOL CHALLENGE IN CANNABIS USERS AND NON-USERS DIFFERENTIALLY AFFECTS BRAIN FUNCTION AND BEHAVIOR: AN FMRI STUDY OF DEVELOPMENT OF TOLERANCE
por: Colizzi, Marco, et al.
Publicado: (2018)

Adversity in childhood linked to elevated striatal dopamine function in adulthood
por: Egerton, Alice, et al.
Publicado: (2016)

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
por: Colizzi, Marco, et al.
Publicado: (2017)

Cannabinoids, reward processing, and psychosis
por: Gunasekera, Brandon, et al.
Publicado: (2021)

M149. THE TOPOGRAPHY OF STRIATAL DOPAMINE AND SYMPTOMS IN PSYCHOSIS: AN INTEGRATIVE PET AND MRI STUDY
por: McCutcheon, Rob, et al.
Publicado: (2020)

Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis
por: Modinos, Gemma, et al.
Publicado: (2018)

Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function
por: Allen, Paul, et al.
Publicado: (2021)

Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms
por: Modinos, Gemma, et al.
Publicado: (2017)

F102. CHANGE IN PATTERNS OF CANNABIS AND OTHER SUBSTANCE USE OVER TIME IN EARLY PSYCHOSIS- EXAMINING THE EFFECT OF DEVELOPMENT OF PSYCHOSIS
por: Sami, Musa, et al.
Publicado: (2018)

Factors Moderating the Association between Cannabis Use and Psychosis Risk: A Systematic Review
por: van der Steur, Sanne J., et al.
Publicado: (2020)

F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?
por: Oliver, Dominic, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_62l772cflchj112ondik9h0pn5